Nucl Med Mol Imaging.
2025 Feb;59(1):8-26. 10.1007/s13139-024-00886-x.
Radioactive Iodine Therapy in Differentiated Thyroid Cancer: Summary of the Korean Thyroid Association Guidelines 2024 from Nuclear Medicine Perspective, Part-II
- Affiliations
-
- 1Department of Nuclear Medicine, Seoul National University Boramae Medical Center, Seoul, Korea
- 2Department of Nuclear Medicine, National Cancer Center, Goyang, Korea
- 3Department of Nuclear Medicine, Chosun University Hospital, Gwangju, Korea
- 4Department of Nuclear Medicine, Pusan National University Hospital, Busan, Korea
- 5Department of Nuclear Medicine, CHA Bundang Medical Center, Seongnam, Korea
- 6Department of Nuclear Medicine, Chungnam National University Sejong Hospital, Sejong, Korea
- 7Department of Nuclear Medicine, Kyungpook National University Hospital, Daegu, Korea
- 8Department of Nuclear Medicine, Kyungpook National University Chilgok Hospital, Daegu, Korea
- KMID: 2565519
- DOI: http://doi.org/10.1007/s13139-024-00886-x
Abstract
- Thyroid cancer, one of the most common endocrine tumors, generally has a favorable prognosis but remains a significant medical and societal concern due to its high incidence. Early diagnosis and treatment of differentiated thyroid cancer (DTC) significantly affect long-term outcomes, requiring the selection and application of appropriate initial treatments to improve prognosis and quality of life. Recent advances in technology and health information systems have enhanced our understanding of the molecular genetics of thyroid cancer, facilitating the identification of aggressive subgroups and enabling the accumulation of research on risk factors through big data. The Korean Thyroid Association (KTA) has revised the “KTA Guidelines on the Management of Differentiated Thyroid Cancers 2024” to incorporate these advances, which were developed by a multidisciplinary team and underwent extensive review and approval processes by various academic societies. This article summarizes the 2024 KTA guidelines for radioactive iodine (RAI) therapy in patients with DTC, written by the Nuclear Medicine members of the KTA Guideline Committee, and covers RAI therapy as initial management of DTC and RAI therapy in advanced thyroid cancer.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Patient Preparation and Special Consideration before Radioactive Iodine Therapy
- Nuclear Medicine Imaging in Differentiated Thyroid Cancer: Summary of the Korean Thyroid Association Guidelines 2024 from Nuclear Medicine Perspective, Part‑I
- Differentiated Thyroid Cancer and Radioactive Iodine: Past, Present and Future
- Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer
- Diagnostic and Therapeutic Approaches to Radioactive Iodine Refractory Differentiated Thyroid Cancer
